Stockholm3 blood test prevents unnecessary prostate biopsies across ethnicities

Results from a recently presented study found that the Stockhom3 blood test for prostate cancer risk stratification reduces unnecessary prostate biopsies and diagnoses of grade 1 prostate cancers. The multi-ethnic study included Black, White, Hispanic, and Asian individuals.

The researchers aimed to validate the test’s noninferiority in detecting clinically significant prostate cancer compared to PSA testing. The researchers also wanted to prove the efficacy of the test versus PSA testing to reduce the number of biopsies in men with benign or grade 1 biopsies.